Nothing Special   »   [go: up one dir, main page]

Rao et al., 2018 - Google Patents

Spontaneous development of Alzheimer's disease‐associated brain pathology in a Shugoshin‐1 mouse cohesinopathy model

Rao et al., 2018

View PDF
Document ID
14232484564478018564
Author
Rao C
Farooqui M
Zhang Y
Asch A
Yamada H
Publication year
Publication venue
Aging Cell

External Links

Snippet

Spontaneous late‐onset Alzheimer's disease (LOAD) accounts for more than 95% of all human AD. As mice do not normally develop AD and as understanding on molecular processes leading to spontaneous LOAD has been insufficient to successfully model LOAD …
Continue reading at onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material

Similar Documents

Publication Publication Date Title
Bao et al. Loss of ferroportin induces memory impairment by promoting ferroptosis in Alzheimer’s disease
Rao et al. Spontaneous development of Alzheimer's disease‐associated brain pathology in a Shugoshin‐1 mouse cohesinopathy model
Tsai et al. PLCG2 is associated with the inflammatory response and is induced by amyloid plaques in Alzheimer’s disease
Su et al. PGC− 1α promoter methylation in Parkinson’s disease
Yu et al. Apolipoprotein E in Alzheimer's disease: an update
Agrawal et al. SPEG interacts with myotubularin, and its deficiency causes centronuclear myopathy with dilated cardiomyopathy
Villar-Menéndez et al. Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A 2A R levels in Huntington’s disease
Rhinn et al. Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease
Hokama et al. Altered expression of diabetes-related genes in Alzheimer's disease brains: the Hisayama study
Kurz et al. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice
Tiosano et al. Mutations in PIK3C2A cause syndromic short stature, skeletal abnormalities, and cataracts associated with ciliary dysfunction
Liu et al. The investigation of genetic and clinical features in Chinese patients with juvenile amyotrophic lateral sclerosis
Kolisnyk et al. Cholinergic surveillance over hippocampal RNA metabolism and Alzheimer's-like pathology
Errico et al. A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice
Cochran et al. The Alzheimer's disease risk factor CD2AP maintains blood–brain barrier integrity
Edens et al. A novel ALS-associated variant in UBQLN4 regulates motor axon morphogenesis
Farhan et al. Identification of a novel synaptic protein, TMTC3, involved in periventricular nodular heterotopia with intellectual disability and epilepsy
Lu et al. Identification of genes associated with cortical malformation using a transposon-mediated somatic mutagenesis screen in mice
Armstrong et al. Neuropathological heterogeneity in Alzheimer’s disease: a study of 80 cases using principal components analysis
Engstrom et al. The inhibition of LSD1 via sequestration contributes to tau-mediated neurodegeneration
Guo et al. Sex specific molecular networks and key drivers of Alzheimer’s disease
Fowler et al. Leveraging existing data sets to generate new insights into Alzheimer’s disease biology in specific patient subsets
Yan et al. FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease
Rezazadeh et al. Genetic discoveries and advances in late‐onset Alzheimer’s disease
Harerimana et al. The role of mitochondrial genome abundance in Alzheimer's disease